Literature DB >> 20657465

A facile one-pot synthesis of 1-arylpyrazolo[3,4-d]pyrimidin-4-ones.

Xiaohong Zhang1, Qiulian Lin, Ping Zhong.   

Abstract

One pot synthesis of 1-arylpyrazolo[3,4-d]pyrimidin-4-ones by the reaction of 5-amino-N-substituted-1H-pyrazole-4-carbonitrile with different lower aliphatic acids in the presence of POCl(3) has been developed. The structures of all the title compounds have been confirmed by IR, (1)H-NMR, (13)CNMR, and elemental analyses. Moreover, the structures of one of these compounds, 2c, was confirmed by single-crystal X-ray diffraction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20657465      PMCID: PMC6263351          DOI: 10.3390/molecules15053079

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


1. Introduction

Pyrazolopyrimidinone derivatives have attracted the attention of numerous researchers over many years due to their important biological activities [1,2,3,4]. Structural analogs of pyrazolo[3,4-d]- pyrimidines have displayed good activities as inhibitors of cyclin-dependent kinase 2 [5] and PI3 kinase-A [6], anticancer and radioprotective activity [7], antimicrobial [8] and other biology activity [9]. The importance of pyrazolo[3, 4-d]pyrimidines had resulted in the development of several synthetic methods for their construction [10,11]. The traditional transformation utilizes two steps to assemble aminopyrazolo[3, 4-d] pyrimidin-4-ones, as illustrated in Scheme 1 and Scheme 2. However, the transformation of compounds 2 requires two steps and sufferes from several disadvantages such as vigorous conditions, long reaction times and low yields [12,13]. The development of one-step and efficient syntheses of aminopyrazolo[3,4-d]pyrimidin-4-ones under mild conditions remained a work in progress.
Scheme 1

Synthesis of pyrazolo [3, 4-d] pyrimidin-4-ones by the reaction of esters.

Scheme 2

Synthesis of pyrazolo [3, 4-d] pyrimidin-4-ones by the reaction of acyl chlorides.

Synthesis of pyrazolo [3, 4-d] pyrimidin-4-ones by the reaction of esters. Synthesis of pyrazolo [3, 4-d] pyrimidin-4-ones by the reaction of acyl chlorides. Here, we report a simple and efficient method for the synthesis of usefully functionalized pyrazolo[3,4-d] pyrimidins-4-ones 2 by heteroannulation under mild conditions using POCl3.

2. Result and Discussion

The 5-amino-N-substituted-1H-pyrazole-4-carbonitrile starting materials 1, synthesized by a one–pot synthesis literature procedure [14], was then reacted with lower aliphatic acids in the presence of POCl3 to give the target N-substituted pyrazolo[3,4-d]pyrimidin-4-ones 2 (Scheme 3).
Scheme 3

Synthesis of pyrazolo[3, 4-d]pyrimidin-4-ones by the reaction of carboxylic acid in the presence of POCl3.

Synthesis of pyrazolo[3, 4-d]pyrimidin-4-ones by the reaction of carboxylic acid in the presence of POCl3. A number of works about POCl3-catalyzed reactions, especially intramolecular condensations [15] have been reported. In our reaction system POCl3 acted not only as a chlorinating reagent, but also an oxidant. Thus, we concluded that the 5-amino-N-substituted-1H-pyrazole-4-carbonitrile were first oxidized to give the corresponding N-substituted-5-amino-pyrazole-4-carboxamide, which immediately reacted with the acyl chloride which might be generated in situ from the reaction of the carboxylic acid with POCl3. Followed by cyclization and condensation of the intermediate, the target products were formed. The reaction went smoothly by controlling the amount of POCl3, and the products were obtained in good yields. The results were presented in Table 1.
Table 1

N-substituted prazolo[3, 4-d]pyrimidin-4-one 2a-j via Scheme 3.

EntryR2R1Yield aTime(h)
2 a H2,6-Cl2-4-CF3-C6H2-901.5
2 b CH32,6-Cl2-4-CF3-C6H2-872
2 c CH2CH32,6-Cl2-4-CF3-C6H2-902.5
2 d CCl32,6-Cl2-4-CF3-C6H2-892
2 e CH34-OCH3-C6H4-831
2 f CH32,4-(NO2)2-C6H3-901.5
2 g CH32,4,6-Cl3-C6H2-971.5
2h CH32-Cl-C6H4-822
2 i CH3H752.5
2 j CH3n-Bu702.5
a isolated yields based on compound 2
N-substituted prazolo[3, 4-d]pyrimidin-4-one 2a-j via Scheme 3. The structures of compounds 2a-j were deduced from their elemental analyses and their IR, 1H- NMR, 13C-NMR and mass spectra and all elemental and spectral data of compounds 2a-j were in accord with the suggested structures. The 1H-NMR spectrum of 2c, as an example, consisted of a singlet at δ 11.06 from the NH function, a singlet at δ 8.27 is from the H-3 proton, a singlet at δ 8.11 due to the phenyl ring (two protons), a multiplet at δ 2.74 (two protons) from the CH2 and a triplet at δ 1.23 due to the methyl group (three protons). Moreover the structure of 2c was confirmed via X-ray crystallographic analysis (Figure 1).
Figure 1

Single crystal X-ray crystal structure of 2c.

Single crystal X-ray crystal structure of 2c.

3. Experimental

3.1. General

All the melting points were uncorrected. 1H-, 13C-, and 19F-NMR spectra were recorded on a FT-Bruker AT-300 instrument using CDCl3 or CD3COCD3 as a solvent with tetramethylsilane (TMS) as the internal standard. J-values are given in Hz. Compounds were properly characterized by elemental analyses using a Carlo-Erba EA-1112 instrument. IR spectra were measured on a Bruker VECTOR55 instrument. Silica gel 60 GF254 was used for analytical and preparative TLC.

3.2. General procedure for the preparation of the pyrazolo[3,4-d]pyrimidines : preparation of 2c

5-Amino-1-[2,6-dichloro-4-(trifloromethyl)phenyl]-1H-pyrazole-4-carbonitrile (0.321 g, 1 mmol) was dissolved in propanoic acid (3 mL). Then POCl3 (0.2 mL) was added quickly. The mixture was refluxed for 2 h (the reaction system was carefully observed by TLC). After the mixture was cooled, added ice water (50 mL). A mass of white precipitate was produced. K2CO3 was added to neutralize the acid till no bubble occurs. The reaction mixture was filtered, and washed with a small amount of ethanol, dried. A 90% yield of the compound was obtained. Crystals of 2c suitable for X-ray diffraction were obtained by slow evaporation of ethanol-acetone mixture solution. The other compounds were also synthesized according to this method. 1-(2,6-Dichloro-4-(trifluoromethyphenyl]-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one (2a): White solid; mp 271-273 ºC, IR (KBr, cm-1): 3849, 3749, 2924, 1699, 1592, 681; 1H-NMR (CD3COCD3, 300 MHz): δ 11.32 (s, 1H), 8.36 (s, 1H), 8.15 (s, 1H), 8.12 (s, 2H); 13C-NMR (CD3COCD3, 75 MHz): δ 106.3 (1C), 122.4 (q, J = 272 Hz, 1C), 126.4 (1C), 132.7 (q, J = 33.75 Hz, 1C), 135.5 (2C), 136.1 (1C), 137.8 (2C), 149.8 (1C), 153.8 (1C), 157.0 (1C); MS: m/z (%) = 348 (100, [M+]). Anal. Calcd. for C12H5Cl2F3N4O: C, 41.29; H, 1.44; N, 16.05. Found: C, 41.20; H, 1.45; N, 16.00%. 6-Methyl-1-(2,6-dichloro-4-trifluoromethylphenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one (2b): White solid; mp 259-260 ºC, IR (KBr, cm-1): 3772, 3105, 2896, 1598, 1392, 1317, 1131; 1H-NMR (DMSO-d6, 300 MHz): δ 12.42 (s, 1H), 8.40 (s, 1H), 8.27 (s, 2H), 2.31 (s, 3H); 13C-NMR (DMSO-d6, 75 MHz): δ 21.2 (1C), 104.3 (1C), 122.2 (q, J = 272 Hz, 1C), 126.4 (1C), 132.6 (q, J = 33.70 Hz, 1C), 135.6 (2C), 136.3 (1C), 137.6 (2C), 154.5 (1C), 157.6 (1C), 159.8 (1C); MS: m/z (%) = 361 (100, [M+ - 1]); Anal. Calcd for C13H7Cl2F3N4O: C, 43.00; H, 1.94; N, 15.43. Found: C, 42.91; H, 1.90, N, 15.38. 6-Ethyl-1-(2,6-dichloro-4-trifluoromethylphenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one (2c): White solid; mp 232-233 ºC, IR (KBr, cm-1): 3094, 2989, 1681, 1598, 1531, 1319, 1173, 1124, 1H-NMR (CD3COCD3, 300 MHz): δ 11.16 (s, 1H), 8.27 (s, 1H), 8.11 (s, 2H), 2.74 (q, J = 7.5 Hz, 2H), 1.23 (t, J = 7.5 Hz, 3H); 13C-NMR (DMSO-d6, 75 MHz): δ 11.8 (1C), 27.8 (1C), 104.6 (1C), 122.4 (q, J = 272 Hz, 1C), 126.5 (1C), 132.7 (q, J= 33.75 Hz, 1C), 135.7 (2C), 136.5 (1C), 137.7 (2C), 154.6 (1C), 158.0 (1C), 164.1 (1C); MS: m/z (%) = 375 (100, [M+ - 1]); Anal. Calcd for C14H9Cl2F3N4O: C, 44.59; H, 2.41; N, 14.86. Found: C, 44.51; H, 2.36, N, 14.83. 6-Trichloromethyl-1-(2,6-dichloro-4-trifluoromethylphenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]- pyrimid- in-4-one (2d): White solid; mp 238-239 ºC, IR (KBr, cm-1): 3013, 2920, 1683, 1589, 1333, 1317, 1124, 663, 1H-NMR (DMSO-d6, 300 MHz): δ 12.50 (s, 1H), 8.45 (s, 1H), 8.24 (s, 2H); 13C-NMR (DMSO-d6, 75 MHz): 79.0 (1C), 105.6 (1C), 122.6 (q, J = 273 Hz, 1C), 126.8 (1C), 132.9 (q, J = 33.75 Hz, 1C), 136.0 (2C), 137.0 (1C), 138.1 (2C), 155.3 (1C), 159.0 (1C), 164.7 (1C); MS: m/z (%) = 463 (100, [M+ - 1]); Anal. Calcd for C13H4Cl5F3N4O: C, 33.47; H, 0.86; N, 12.01. Found: C, 33.451; H, 0.85, N, 12.05. 6-Methyl-1-(4-methyloxyphenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one (2e): White solid, mp 258-260 ºC; IR (KBr, cm-1): 3850, 3745, 3618, 2926, 1690 (s), 1518, 1463, 675 ; 1H-NMR (DMSO-d6, 300 MHz): δ 12.23 (s, 1H), 8.19, (s, 1H), 7.86 (d, J = 7.5 Hz, 2H), 7.08 (d, J = 7.5 Hz, 2H), 3.80 (s, 3H), 2.37 (s, 3H); 13C-NMR (DMSO-d6, 75 MHz): δ 21.5 (1C), 55.5 (1C), 105.2 (1C), 114.3 (2C), 123.5 (2C), 131.5 (1C), 135.3 (1C), 152.1 (1C), 157.9 (1C), 158.1 (1C), 158.3 (1C); MS: m/z (%) = 255 (100, [M+ - 1]); Anal. Calcd for C13H12N4O2: C, 60.93; H, 4.72; N, 21.86. Found: C, 60.88; H, 4.68, N, 21.76. 6-Methyl-1-(2,4-dinitrophenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one (2f): Yellow solid, mp 229-230ºC; IR (KBr, cm-1): 3749, 2921, 1695(s), 1605, 1533, 1348 ; 1H-NMR (DMSO-d6, 300 MHz): δ 12.52 (s, 1H), 8.85 (s, 1H), 8.70 (d, J = 9 Hz, 1H), 8.37 (s, 1H), 8.19 (d, J = 9 Hz, 1H), 2.44 (s, 3H); 13C-NMR (DMSO-d6, 75 MHz): δ 21.5 (1C), 105.6 (1C), 121.3 (1C), 128.5 (1C), 128.8 (1C), 134.1 (1C), 138.4 (1C), 143.3 (1C), 146.1 (1C), 153.9 (1C), 157.5 (1C), 160.1 (1C); MS: m/z (%) = 315 (100, [M+ - 1]); Anal. Calcd for C12H8N6O5: C, 45.58; H, 2.55; N, 26.58. Found: C, 45.45; H, 2.50, N, 26.46. 6-Methyl-1-(2,4,6-trichlorophenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one (2g): White solid, mp 236-237 ºC; IR (KBr, cm-1): 3432, 1685, 1599, 1536, 1386, 667; 1H-NMR (DMSO-d6, 300 MHz): δ 12.4 (s, 1H), 8.3 (s, 1H), 8.0 (s, 2H), 2.3 (s, 3H); 13C-NMR (DMSO-d6, 75 MHz): δ 21.4 (1C), 104.4 (1C), 129.2 (2C), 132.2 (1C), 135.4 (2C), 136.4 (1C), 137.4 (1C), 154.6 (1C), 1587.9 (1C), 159.7 (1C); MS: m/z (%) = 327 (100, [M+ - 1]); Anal. Calcd for C12H7Cl3N4O: C, 43.73; H, 2.14; N, 17.00. Found: C, 43.67; H, 2.10, N, 16.88. 6-Methyl-1-(2-chlorophenyl)-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one (2h): White solid, mp 217-219 ºC; IR (KBr, cm-1): 3840, 3745, 2929, 1693, 1602, 1520; 1H-NMR (DMSO-d6, 300 MHz): δ 12.3 (s, 1H), 8.2 (s, 1H), 7.6 (m, 4H), 2.3 (s, 3H); 13C-NMR (DMSO-d6, 75 MHz): δ 21.2 (1C), 104.2 (1C), 128.1 (1C), 130.2 (2C), 131.2 (1C), 131.4 (1C), 134.9 (1C), 136.0 (1C), 153.9 (1C), 157.9 (1C), 158.8 (1C); MS: m/z (%) = 259 (100, [M+ - 1]); Anal. Calcd for C12H9ClN4O: C, 55.29; H, 3.84; N, 21.49. Found: C, 55.12; H, 3.80, N, 21.36. 6-Methyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one (2i): White solid, mp 264-265 ºC; IR (KBr, cm-1): 3842, 2925, 2272, 1741, 1645, 1518, 1461, 1391, 1121, 669; 1H-NMR (DMSO-d6, 300 MHz): δ12.03 (s, 1H), 10.36 (s,1H), 8.33 (s, 1H), 2.36 (s, 3H); 13C-NMR (DMSO-d6, 75 MHz): 22.0(1C), 105.00 (1C), 135.17 (1C), 153.70 (1C), 158.78 (1C), 159.20 (1C); MS: m/z (%) = 149 (100, [M+ - 1]); Anal. Calcd for C6H6N4O: C, 48.00; H, 4.03; N, 37.32. Found: C, 47.95; H, 4.00, N, 37.28. 6-Methyl-1-n-butyl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one (2j), White solid, mp 144-145 ºC; IR (KBr, cm-1):2925, 2855, 1387, 1120, 676; 1H-NMR (CD3COCD3): δ 11.60 (s, 1H), 8.44 (s, 1H), 4.20 (t, J = 6.8 Hz, 2H), 2.26 (s, 3H), 1.78 (m, J = 10.6 Hz, 2H), 1.20 (m, J = 7.41Hz, 2H), 0.86 (t, J = 7.4 Hz, 3H); 13C-NMR (CD3COCD3): 13.36 (1C), 19.09 (1C), 21.43 (1C), 31.50 (1C), 52.1 (1C), 104.73 (1C), 128.46 (1C), 155.52 (1C), 159.24 (1C), 159.32 (1C); MS: m/z (%) = 205 (100, [M+ - 1]); Anal. Calcd for C10H14N4O: C, 58.24; H, 6.84; N, 27.16. Found: C, 58.20; H, 6.80, N, 27.10.

3.3. X-ray crystallography

Compound 2c was subjected to single crystal X-ray crystallography and intensity data were collected at 298(2)K on an Siemens P4 diffractometer and use graphite Monochromated MoKa adiation (λ = 0.71073Å). The structure was solved by a direct method using the SHELXL-97 program [16] and refined with the SHELXL-97 program. All H atoms bonded to the C atoms were placed geometrically at the distances of 0.93–0.96Å and included in the refinementin riding motion approximation with Uiso (H) = 1.2 or 1.5Ueq of the carrier atom. The thermal ellipsoids were plotted with the SHELXL-97 program at 50% probability. The molecular structure is shown in Figure 1. Selected crystal data and structure refinement details are presented in Table 2. Selected bond distances and angles are listed in Table 3.
Table 2

Crystal data and structure refinement for C14H9Cl2F3N4O.

Empirical formulaC14 H9 Cl2 F3 N4 O
Formula weight377.15
Temperature298(2) K
Wavelength0.71073 A
Crystal systemMonoclinic
space groupP 2/n
Unit cell dimensions a = 13.468(4) A alpha = 90 deg.
b = 8.234(3) A beta = 112.056(6) deg.
c = 15.047(5) A gamma = 90 deg
Volume1546.4(9)A3
Z4
Absorption coefficient0.463 mm-1
F(000)760
Theta range for data collection2.47° to 25.02°
Limiting indices-16<=h<=15, -9<=k<=9, -17<=l<=14
Reflections collected / unique7730 / 2740 [R(int) = 0.0213]
Completeness to theta = 25.0299.6%
Absorption correctionSemi-empirical from equivalents
Max. and min. transmission0.9214 and 0.8154
Refinement methodFull-matrix least-squares on F2
Data / restraints / parameters2740 / 0 / 218
Goodness-of-fit on F^21.142
Final R indices [I>2sigma(I)]R1 = 0.0866, wR2 = 0.2087
R indices (all data)R1 = 0.0945, wR2 = 0.2142
Largest diff. peak and hole0.660 and -0.897 e.A-3
Table 3

Selected bond distances (Å) and angles (°) for compound 2c.

F(1)-C(1)1.341(6)O(1)-C(10)1.236(5)N(1)-C(11)1.369(6)
N(2)-C(12)1.355(6)N(3)-C(8)1.310(6)N(4)-C(8)1.368(6)
C(1)-C(2)1.504(7)C(2)-C(7)1.360(7)C(4)-C(5)1.388(6)
C(6)-C(7)1.377(7)C(9)-C(10)1.436(6)C(9)-C(12)1.388(6)
C(11)-N(1)-C(10)125.1(4)C(8)-N(3)-C(9)110.2(4)C(12)-N(4)-C(5)127.9(4)
C(8)-N(4)-C(5)120.2(3)C(7)-C(2)-C(3)120.3(4)C(3)-C(2)-C(1)119.3(4)
C(4)-C(3)-C(2)119.8(4)C(6)-C(5)-C(4)117.3(4)C(6)-C(5)-N(4)120.3(4)
N(3)-C(8)-N(4)106.8(4)C(12)-C(9)-C(10) 117.6(4)N(1)-C(10)-C(9)112.1(4)
N(2)-C(11)-N(1)123.9(4)N(1)-C(11)-C(13)115.3(4)N(2)-C(12)-C(9)127.9(4)
CCDC 774536 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge, CB2 1EZ, UK; E-mail: deposit@ccdc.cam.ac.uk. Crystal data and structure refinement for C14H9Cl2F3N4O. Selected bond distances (Å) and angles (°) for compound 2c.

4. Conclusions

In summary, we have successfully developed a simple and efficient method for the synthesis of variously functionalized pyrazolo[3,4-d]pyrimidin-4-ones by heteroannulation under mild conditions using POCl3. This works has been patented [17]. Further heteroannulation studies are underway in our laboratory.
  4 in total

Review 1.  Transition metal-free one-pot synthesis of nitrogen-containing heterocycles.

Authors:  Simpal Kumari; Dharma Kishore; Sarvesh Paliwal; Rajani Chauhan; Jaya Dwivedi; Aakanksha Mishra
Journal:  Mol Divers       Date:  2015-06-09       Impact factor: 2.943

2.  Design, Synthesis, and Antitumor Evaluation of Novel Pyrazolo[3,4-d]pyrimidine Derivatives.

Authors:  Manal M Kandeel; Lamia W Mohamed; Mohammed K Abd El Hamid; Ahmed T Negmeldin
Journal:  Sci Pharm       Date:  2012-06-25

Review 3.  5-Aminopyrazole as precursor in design and synthesis of fused pyrazoloazines.

Authors:  Ranjana Aggarwal; Suresh Kumar
Journal:  Beilstein J Org Chem       Date:  2018-01-25       Impact factor: 2.883

4.  Design, Synthesis, and Biological Evaluation of a Novel VEGFR-2 Inhibitor Based on a 1,2,5-Oxadiazole-2-Oxide Scaffold with MAPK Signaling Pathway Inhibition.

Authors:  Mater H Mahnashi; Fardous F El-Senduny; Mohammed Abdulrahman Alshahrani; Mahrous A Abou-Salim
Journal:  Pharmaceuticals (Basel)       Date:  2022-02-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.